We were delighted to speak with Michael Sperling (Thomas Jefferson University, Philadelphia, PA, USA) to discuss the recent post-hoc analysis of cenobamate for uncontrolled focal seizures, and its intended place in the treatment landscape for epilepsy.
The abstract entitled: ‘Efficacy of Cenobamate for Uncontrolled Focal Seizures: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study’ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
- What did the findings of the recent global, open-label phase 3 study teach us about the efficacy and safety of cenobamate? (0:15)
- What is the rationale for the dose escalating strategy with cenobamate? (5:45)
- What was the rationale for the post-hoc analysis? (6:47)
- What were the findings of this analysis? (7:41)
- What questions remain unanswered? (8:45)
Disclosures: Michael Sperling has received compensation for speaking at CME programs from Neurology Live, Medscape, Projects for Knowledge, International Medical Press, Eisai, and UCB Pharma; and is an advisor for scientific publications for Neurelis; consults for Medtronic with payments to Thomas Jefferson University; and has received research support from Eisai; Medtronic; Neurelis; SK Life Science; Takeda; Xenon; Cerevel; UCB Pharma; and Engage Pharmaceuticals.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
Share this Video
Related Videos In Epilepsy
Mary Koenig, AES 2021: Ganaxolone for the Treatment of Tuberous Sclerosis Complex
touchNEUROLOGY met with Professor Mary Koenig (McGovern Medical School, UTHealth, Houston, TX, USA) to discuss the efficacy and safety findings from the phase 2 Violet study, investigating oral ganaxalone in PCDH19-Clustering Epilepsy (NCT03865732). The abstract ‘Phase 2 Open-label Clinical Study Evaluating Oral Ganaxolone for the Treatment of Seizures Associated with Tuberous Sclerosis Complex‘ (Abstract number: […]
Monica Ferrer Socorro & Jacqueline French, AES 2021: Delayed Diagnosis in Childhood- vs. Adult-Onset Focal Epilepsy
It was a great pleasure to meet with both Dr Monica Ferrer Socorro (NYU Langone Health, New York City, NY, USA) and Prof. Jacqueline French (NYU Grossman School of Medicine, New York City, NY, USA) to discuss a retrospective analysis investigating focal epilepsy, its clinical presentation in adolescents, highlighting disproportionate delay to diagnosis experienced by […]
Michael Sperling AES, 2021: Diazepam Nasal Spray in Patients with Seizure Clusters – Subgroup Analysis from a Phase 3 Safety Study
touchNEUROLOGY met with Prof. Michael Sperling (Thomas Jefferson University, Philadelphia, PA, USA) to discuss a subgroup analysis from a phase 3 safety study investigating the use of diazepam nasal spray in patients with seizure clusters concomitantly receiving clobazam. Diazepam nasal spray is an FDA-approved nasal spray version of diazepam, indicated for the treatment of acute, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!